Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BLAZE: Bexmarilimab and Nivolumab in Solid Tumours, NSCLC and Melanoma
NCT07718243Phase 2Recruiting
- Sponsor
- The Institute of Cancer Research
- Start
- Aug 2026
- Primary completion
- Jan 2030
- Countries
- 1
01
Overview
A Phase 2 trial of bexmarilimab in solid tumor, non-small cell lung cancer (NSCLC), melanoma, sponsored by The Institute of Cancer Research. Started Aug 2026; status: recruiting.
02
Drugs
bexmarilimab
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)melanoma
Beyond the preview
Go deeper on NCT07718243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07718243.